1.99
-0.14(-6.57%)
Currency In USD
| Previous Close | 2.13 |
| Open | 2.14 |
| Day High | 2.15 |
| Day Low | 1.99 |
| 52-Week High | 5.38 |
| 52-Week Low | 1.23 |
| Volume | 423,223 |
| Average Volume | 548,791 |
| Market Cap | 74.39M |
| PE | -1.08 |
| EPS | -1.85 |
| Moving Average 50 Days | 1.64 |
| Moving Average 200 Days | 2.11 |
| Change | -0.14 |
If you invested $1000 in Metagenomi, Inc. Common Stock (MGX) since IPO date, it would be worth $193.02 as of July 18, 2025 at a share price of $1.99. Whereas If you bought $1000 worth of Metagenomi, Inc. Common Stock (MGX) shares 1 year ago, it would be worth $193.02 as of July 18, 2025 at a share price of $1.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
GlobeNewswire Inc.
May 14, 2025 10:00 AM GMT
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate the ability to specifically inte
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 13, 2025 8:30 PM GMT
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well capitalized with $226.0 million in cash,
Metagenomi to Present at Upcoming Scientific Meetings
GlobeNewswire Inc.
May 02, 2025 11:00 AM GMT
EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that t